AIM ImmunoTech Inc.(AIMI.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
AIM ImmunoTech Inc.
AIMI.US
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc.
1.944 T
AIMI.USMarket value -Rank by Market Cap -/-

Financial Score

26/01/2026 Update
E
BiotechnologyIndustry
Industry Ranking395/397
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-10862.86%E
    • Profit Margin-10416.44%E
    • Gross Margin37.50%B
  • Growth ScoreD
    • Revenue YoY-24.35%E
    • Net Profit YoY51.13%B
    • Total Assets YoY-61.41%E
    • Net Assets YoY-179.92%E
  • Cash ScoreD
    • Cash Flow Margin-0.96%D
    • OCF YoY-24.35%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreE
    • Gearing Ratio161.73%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AIM Vaccine updates on 20-valent pneumococcal polysaccharide conjugate vaccine

    AIM Vaccine updates on 20-valent pneumococcal polysaccharide conjugate vaccine

    marketscreener·
    US
    AIMI
    0.00%
    US
    AIMID
    0.00%
    marketscreener·
    US
    AIMI
    0.00%
    US
    AIMID
    0.00%

    AIM ImmunoTech Announces 1-for-100 Reverse Stock Split to Regain NYSE Compliance

    AIM ImmunoTech Inc. has announced a 1-for-100 reverse stock split effective June 12, 2025, to increase its per-share market price and regain compliance with NYSE American listing requirements. Post-split, the stock will trade under the ticker AIMID on OTC Pink for 20 days. This announcement is for informational purposes only and should not be considered financial advice.

    Reuters·
    US
    AIMI
    0.00%
    US
    AIM
    -5.16%
    US
    AIMID
    0.00%
    Reuters·
    US
    AIMI
    0.00%
    US
    AIM
    -5.16%
    US
    AIMID
    0.00%

    Govt raises financial limits to ease procurement for scientific research

    The government has increased financial limits for procuring scientific equipment and consumables to enhance research capabilities. Vice-chancellors and directors can now purchase items worth up to ₹2 lakh without quotations, and committee purchases have a new limit of ₹25 lakh. The threshold for limited and advertised tender enquiries has risen to ₹1 crore. Additionally, global tender enquiries for research-related procurement can now be approved up to ₹200 crore. These changes aim to reduce delays and promote innovation across various research institutions, including those in defense and health sectors.

    Business Standard·
    US
    AIMI
    0.00%
    US
    AIMID
    0.00%
    Business Standard·
    US
    AIMI
    0.00%
    US
    AIMID
    0.00%

    CHcc releases resources for Hospital-at-Home programs to advance implementation and scale. High-quality care model.

    Today in Boston, on June 4, 2025, the Connected Health Collaborative Community (CHcc) announced the launch of new tools to support industry in implementing and expanding hospital-at-home (HaH) programs. These tools aim to establish HaH as a sustainable and high-quality model of care. This initiative will help improve healthcare services by enhancing access and efficiency. The CHcc is leading efforts to reshape healthcare practices and improve patient outcomes.

    Unusual Whales·
    US
    HCSG
    -0.53%
    US
    AIMI
    0.00%
    Unusual Whales·
    US
    HCSG
    -0.53%
    US
    AIMI
    0.00%

    DPR highlights 3 benefits of integrated contracting for faster GMP facility deployment. - Boston, June 2, 2025

    Specialists are currently examining the impact of early cooperation and creative contracting approaches on speeding up schedules, managing expenses, and enhancing project results. In a recent gathering in Boston on June 2, 2025, experts emphasized the significance of swift action in the realm of life-saving scientific studies. Mike, a key figure in the discussion, stressed, "Time is of the essence", underscoring the urgent nature of their work. Through proactive collaboration and unconventional contractual strategies, they aim to achieve efficiencies in project delivery.

    Unusual Whales·
    US
    AIMI
    0.00%
    Unusual Whales·
    US
    AIMI
    0.00%
    © 2026 Longbridge｜Disclaimer